Royal Bank Of Canada set a $44.00 price target on Flexion Therapeutics, Inc. (NASDAQ:FLXN) in a research report sent to investors on Sunday morning. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.
FLXN has been the topic of several other research reports. Zacks Investment Research upgraded Flexion Therapeutics from a sell rating to a hold rating in a report on Monday, August 28th. ValuEngine upgraded Flexion Therapeutics from a sell rating to a hold rating in a report on Friday, September 1st. Needham & Company LLC restated a buy rating and set a $36.00 price objective on shares of Flexion Therapeutics in a report on Sunday, September 17th. Wells Fargo & Company set a $39.00 price objective on Flexion Therapeutics and gave the stock a buy rating in a report on Friday, October 6th. Finally, BMO Capital Markets restated a buy rating on shares of Flexion Therapeutics in a report on Friday, August 11th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of Buy and an average price target of $88.50.
Flexion Therapeutics (NASDAQ:FLXN) last posted its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.11).
In other news, insider Yamo Deniz bought 3,000 shares of the business’s stock in a transaction that occurred on Friday, September 1st. The shares were acquired at an average cost of $24.15 per share, with a total value of $72,450.00. Following the transaction, the insider now owns 5,000 shares of the company’s stock, valued at approximately $120,750. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders purchased a total of 5,375 shares of company stock worth $131,575 over the last ninety days. Corporate insiders own 15.98% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the stock. Fiduciary Trust Co. purchased a new position in shares of Flexion Therapeutics in the 2nd quarter worth $101,000. IFP Advisors Inc raised its position in shares of Flexion Therapeutics by 24.5% in the 2nd quarter. IFP Advisors Inc now owns 5,080 shares of the specialty pharmaceutical company’s stock worth $103,000 after buying an additional 1,000 shares during the period. Advisor Group Inc. raised its position in shares of Flexion Therapeutics by 205.9% in the 2nd quarter. Advisor Group Inc. now owns 5,200 shares of the specialty pharmaceutical company’s stock worth $105,000 after buying an additional 3,500 shares during the period. State Board of Administration of Florida Retirement System purchased a new position in shares of Flexion Therapeutics in the 3rd quarter worth $235,000. Finally, Voya Investment Management LLC raised its position in shares of Flexion Therapeutics by 25.8% in the 2nd quarter. Voya Investment Management LLC now owns 12,914 shares of the specialty pharmaceutical company’s stock worth $261,000 after buying an additional 2,651 shares during the period. 72.31% of the stock is currently owned by institutional investors and hedge funds.
Flexion Therapeutics Company Profile
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.
What are top analysts saying about Flexion Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Flexion Therapeutics Inc. and related companies.